Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients
Launched by CENTRE D'ETUDES ET DE RECHERCHE POUR L'INTENSIFICATION DU TRAITEMENT DU DIABÈTE · Mar 4, 2008
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
Secondary Objectives :
1. To assess the improvement of blood glucose control and quality of life in patients using the PDA-FIT system
2. To assess the improvement in diabetes care provided by the use of the PDA-FIT system
3. Satisfaction of patients and physicians towards the PDA-FIT system
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • type 1 diabetes mellitus for ≥ 12 months or more (including C-peptide negative secondary diabetes)
- • age \> 18 y.o.
- • intensive insulin basal-bolus therapy for ≥ 6 months. At inclusion, patients should be treated, either with a combination of a basal, long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump
- • chronically uncontrolled diabetes with HbA1c ≥ 8 % during the past 12 months and at inclusion
- Exclusion Criteria:
- • patient with unstable associated evolutive pathology
- • patient who need a more frequent diabetic follow up (than in the protocol)
- • patient with a education teaching within the 3 months before inclusion
- • patient with a hemoglobinopathy
- • patient with toxicomania, alcoholism or psychological troubles
- • type 2 diabetes patients
- • patient who don't need strict metabolic objectives
- • pregnant or parturient women
- • person with no freedom (prisoner)
About Centre D'etudes Et De Recherche Pour L'intensification Du Traitement Du Diabète
The Centre d'Études et de Recherche pour l'Intensification du Traitement du Diabète (CERITD) is a leading clinical trial sponsor dedicated to advancing diabetes treatment through innovative research and rigorous clinical studies. With a focus on improving patient outcomes, CERITD collaborates with healthcare professionals, academic institutions, and industry partners to explore new therapeutic strategies and enhance existing interventions for diabetes management. By prioritizing scientific excellence and patient-centric approaches, CERITD aims to contribute significantly to the understanding and treatment of diabetes, ultimately fostering improved quality of life for individuals affected by this chronic condition.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pessac, , France
Saint Etienne, , France
Montpellier, , France
Paris, , France
Lille, , France
Paris, , France
Nantes, , France
Toulouse, , France
Lyon, , France
Belfort, , France
Besancon, , France
Corbeil Essonnes, , France
Grenoble, , France
Marseille, , France
Nancy, , France
Paris, , France
Rennes, , France
Strasbourg, , France
Patients applied
Trial Officials
Pierre Yves BENHAMOU, MD PHD
Study Chair
University Hospital, Grenoble
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials